Healthcare technology sells into one of the most cautious, multi-stakeholder buying processes in B2B — clinical leads, procurement, IT, compliance, and finance, often five separate people who each have to sign off. Deals routinely take six to twelve months, gated by security reviews and regulatory checks. It's a fair question for a healthcare tech founder to ask: does AI search visibility even matter here, in a market that moves this slowly and carefully?
The evidence says it matters more than most healthcare tech teams currently assume — for reasons specific to this industry, not just because "AI is everywhere now." (Running a patient-facing practice rather than selling software to healthcare organizations? See our companion piece on why patients are choosing a different doctor based on reviews and AI instead.)
The Shortlist Is Forming Before Anyone Reaches Out
A 2026 buyer's journey study surveying nearly 18,000 global business buyers found that generative AI and conversational search have become the most meaningful source of vendor research overall — ranking ahead of vendor websites, product experts, and sales representatives combined. For healthcare vendors specifically, the practical implication is direct: buying committees are researching, comparing, and often forming an initial shortlist inside an AI conversation before your team ever gets a first touchpoint.
This matters more in healthcare than in most industries specifically because of how long and cautious the buying cycle already is. If a vendor is quietly excluded from that early, AI-assisted research phase, there may be no later opportunity to correct it — the shortlist that gets built in month one often survives all the way to the final decision in month nine.
This isn't a hypothetical shift, either. OpenEvidence, a medical AI search platform founded by Daniel Nadler (who previously built and sold Kensho to S&P Global for $550 million), has seen rapid organic adoption among clinicians — a real, current example of how quickly healthcare professionals have moved toward AI-powered tools for research, not just patient-facing use cases. The same underlying shift in behavior extends to how healthcare organizations research vendors and technology purchases, not only clinical information.
Healthcare Has a Risk Most Other Industries Don't: Being Misrepresented, Not Just Missed
For most B2B categories, the AEO risk is invisibility — you simply don't get mentioned. Healthcare technology carries an additional, sharper risk: AI systems can actively misstate what your product does, what it's accredited for, or what clinical evidence supports it, if your own content isn't structured clearly enough for an AI system to represent it accurately.
This isn't a hypothetical concern — dedicated AEO monitoring tools built specifically for healthcare now track "positioning accuracy" as a distinct metric, precisely because AI systems have been found to misstate a provider's specializations, accreditations, or a healthtech product's clinical evidence when the underlying source content is ambiguous. In a regulated space, an AI system inaccurately describing your product's capabilities isn't just a missed lead — it's a genuine compliance and trust problem, one that a generic SaaS company in a less-regulated category simply doesn't have to think about in the same way.
Which Platforms Actually Matter Here
A March–April 2026 survey of over 600 US B2B professionals found ChatGPT the clear leader for product research (71% of respondents use it for this specifically), followed by Google Gemini (61%), Microsoft Copilot (45%), Perplexity (18%), and Claude (14%). Healthcare made up roughly 9% of that survey's respondent base — a smaller slice than technology or manufacturing, but a real and growing one, and there's no reason to expect healthcare buyers behave meaningfully differently from the broader B2B pattern here.
The practical takeaway: ChatGPT and Gemini deserve first priority for most healthcare tech vendors, but cross-platform visibility still matters, since buying committees — especially ones with five separate stakeholders — are unlikely to all be using the exact same tool.
The Cost of Getting This Wrong Is Already Measurable
Separately, healthcare marketing benchmarks put average cost-per-lead for healthcare software and technology at roughly $130, compared to over $600 for medical equipment — and US healthcare and pharma digital ad spend is projected to reach roughly $26.2 billion in 2026, overtaking traditional advertising spend in the category for the first time. Budget is moving toward digital, and increasingly toward the AI-mediated layer of digital, faster than many healthcare marketing teams have adjusted their strategy to match.
What This Actually Means for a Healthcare Tech Team
None of this requires abandoning the careful, compliance-aware approach healthcare marketing already requires — if anything, it reinforces it. The practical priorities:
- Structure content so AI systems can represent it accurately — clear, unambiguous descriptions of what your product does, what it's certified or accredited for, and what evidence supports clinical claims. This protects against misrepresentation, not just invisibility.
- Prioritize ChatGPT and Gemini first, given where healthcare buyer research activity concentrates, while still maintaining basic visibility elsewhere.
- Treat this as a compliance-adjacent workstream, not purely a marketing one — given the misrepresentation risk, it's worth involving whoever owns regulatory/compliance review in how AI-facing content gets structured, the same way that team would review any other public claim about the product.
- Start early relative to the sales cycle — since the shortlist often forms months before outreach begins, this isn't something to address only once a deal is already in motion.
If you're weighing this same question for B2B SaaS more broadly rather than healthcare specifically, see our companion piece on whether AEO actually matters for B2B SaaS — the underlying visibility argument is similar, though healthcare's compliance risk is its own added dimension. For the actual data behind how often this shows up in practice, see our original research on why 50% of top-ranking healthcare companies also get recommended by AI. Ongoing execution — tracking whether AI systems are representing your product accurately across platforms — is also part of what we cover in AI visibility tracking.
Frequently Asked Questions
It's relevant to both, but healthcare carries an added dimension general SaaS doesn't: the risk of AI systems inaccurately representing clinical claims or accreditations, which makes this a compliance consideration as well as a visibility one.
Current data points to ChatGPT and Google Gemini as the highest-usage platforms for B2B product research generally; healthcare buyers are a smaller but real segment of that same behavior, so prioritizing those two platforms first is reasonable, with broader visibility as a secondary goal.
Since AI-assisted research tends to happen early — often before a vendor is ever contacted — AEO work is most valuable when it happens ahead of or alongside early-stage marketing, not as something bolted on once a deal is already in the pipeline.
Yes — dedicated monitoring tools for healthcare AEO specifically track this risk, since AI systems can misstate specializations, accreditations, or clinical evidence when source content is unclear or poorly structured. This is a genuine reason to treat AI-facing content with the same care as any other public compliance-reviewed claim.
The opposite, if anything — a longer cycle means an early misstep (being missed, or being misrepresented) has more time to compound before there's a natural opportunity to correct it.
Want expert help growing your business? Book a discovery call with SweetReed →
